Skip to Content

Notice

Bulk Manufacturer of Controlled Substances Application: Sigma Aldrich Research Biochemicals, Inc.

Document Details

Information about this document as published in the Federal Register.

Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

ACTION:

Notice of application.

DATES:

Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before June 26, 2017.

ADDRESSES:

Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrissette Drive, Springfield, Virginia 22152.

End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (“Assistant Administrator”) pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on December 19, 2016, Sigma Aldrich Research Biochemicals, Inc., 1-3 Strathmore Road, Natick, Massachusetts 01760-2447 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

Controlled substanceDrug codeSchedule
Cathinone1235I
Methcathinone1237I
Mephedrone (4-Methyl-N-methylcathinone)1248I
Aminorex1585I
Alpha-ethyltryptamine7249I
Lysergic acid diethylamide7315I
Tetrahydrocannabinols7370I
4-Bromo-2,5-dimethoxyamphetamine7391I
4-Bromo-2,5-dimethoxyphenethylamine7392I
4-Methyl-2,5-dimethoxyamphetamine7395I
2,5-Dimethoxyamphetamine7396I
3,4-Methylenedioxyamphetamine7400I
N-Hydroxy-3,4-methylenedioxyamphetamine7402I
3,4-Methylenedioxy-N-ethylamphetamine7404I
3,4-Methylenedioxymethamphetamine7405I
Dimethyltryptamine7435I
Psilocybin7437I
5-Methoxy-N,N-diisopropyltryptamine7439I
1-[1-(2-Thienyl)cyclohexyl]piperidine7470I
N-Benzylpiperazine7493I
MDPV (3,4-Methylenedioxypyrovalerone)7535I
Methylone (3,4-Methylenedioxy-N-methylcathinone)7540I
Heroin9200I
Normorphine9313I
Norlevorphanol9634I
Amphetamine1100II
Methamphetamine1105II
Nabilone7379II
1-Phenylcyclohexylamine7460II
Phencyclidine7471II
Cocaine9041II
Codeine9050II
Ecgonine9180II
Start Printed Page 19086
Levomethorphan9210II
Levorphanol9220II
Meperidine9230II
Metazocine9240II
Methadone9250II
Morphine9300II
Thebaine9333II
Levo-alphacetylmethadol9648II
Remifentanil9739II
Sufentanil9740II
Carfentanil9743II
Fentanyl9801II

The company plans to manufacture reference standards.

Start Signature

Dated: April 18, 2017.

Louis J. Milione,

Assistant Administrator.

End Signature End Supplemental Information

[FR Doc. 2017-08344 Filed 4-24-17; 8:45 am]

BILLING CODE 4410-09-P